Bms Design Center company information, Employees & Contact Information

Pharmaceutical research and development pipeline Bristol Myers Squibb

Transparency & reporting Bristol Myers Squibb

The Bristol Myers Squibb Foundation Bristol Myers Squibb

Business development leadership team Bristol Myers Squibb

Worldwide locations Bristol Myers Squibb

Independent research Bristol Myers Squibb

Clinical trials & studies Bristol Myers Squibb

Global Inclusion & Diversity Bristol Myers Squibb

Areas of interest Bristol Myers Squibb

Privacy notice center Bristol Myers Squibb

About us Bristol Myers Squibb

Science Firsthand: Predicting new possibilities in drug discovery Bristol Myers Squibb

Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb

Become a business supplier Bristol Myers Squibb

Our impact Bristol Myers Squibb

Annual reports Bristol Myers Squibb

People and business resource groups Bristol Myers Squibb

Our technologies Bristol Myers Squibb

Research and development center Cambridge, Massachusetts Bristol Myers Squibb

Lynelle B. Hoch Bristol Myers Squibb

Bridging health disparities and transforming lives Bristol Myers Squibb

Women innovators in AI transforming patient care Bristol Myers Squibb

Continuing Innovations on TYK2 Inhibition Bristol Myers Squibb

How BMS employees champion STEM education & diversity Bristol Myers Squibb

Opening Diverse Young Minds for STEM Careers in Pharma Bristol Myers Squibb

Looking to the Future of Cell Therapy Bristol Myers Squibb

Featured Researcher: Michael (Mike) Ellis Bristol Myers Squibb

Exploring New Approaches to Multiple Myeloma Treatment Bristol Myers Squibb

Advances in Hematology with patient-centric approach Bristol Myers Squibb

Meet Greg Meyers: Chief Digital & Technology Officer Bristol Myers Squibb

The future of diversity in clinical trials Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Bristol Myers Squibb

Advancing Research for Treatment of Genitourinary Cancers Bristol Myers Squibb

AI-driven protein degradation research reshaping drug discovery Bristol Myers Squibb

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions Bristol Myers Squibb

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma Bristol Myers Squibb

Advancing Our Breast Cancer Research Bristol Myers Squibb

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Bristol Myers Squibb

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma Bristol Myers Squibb

Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma Bristol Myers Squibb

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb

Hacking R&D: The Role of Artificial Intelligence Bristol Myers Squibb